OncoMatch/Clinical Trials/NCT03633955
Pilot Imaging Study of Leukemia
Is NCT03633955 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies FLT for acute lymphocytic leukemia.
Treatment: FLT — This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Demographics
Lab requirements
Kidney function
serum creatinine < 1.0 or 2x the upper limit of normal (whichever is higher)
Liver function
bilirubin < 2.5 mg/dl, ast/alt <5x upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's National Health System · Washington D.C., District of Columbia
- Emory University · Atlanta, Georgia
- University of Oklahoma Health Sciences Center · Oklahoma City, Oklahoma
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03633955 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 4 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify